Mersana Therapeutics (MRSN) Tops Q3 EPS by 1c

Mersana Therapeutics (NASDAQ: MRSN) reported Q3 EPS of ($0.35), $0.01 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $7.7 million versus the consensus estimate of $9.3 million.

For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.

You May Also Be Interested In

• Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
• Gorilla Technology raises Q2 2026 revenue outlook to $44M
• Jefferies Assumes Allied Blenders (ABDL:IN) at Buy